RESUMEN
BACKGROUND: Major depressive disorder (MDD) is commonly treated with selective serotonin reuptake inhibitors (SSRIs). SSRIs inhibit the serotonin transporter (5-HTT), but the downstream antidepressant mechanism of action of these drugs is poorly understood. The serotonin 1B (5-HT1B) receptor is functionally linked to 5-HTT and 5-HT1B receptor binding and 5-HT1B receptor mRNA is reduced in the raphe nuclei after SSRI administration in primates and rodents, respectively. The effect of SSRI treatment on 5-HT1B receptor binding in patients with MDD has not been examined previously. This positron emission tomography (PET) study aimed to quantify brain 5-HT1B receptor binding changes in vivo after SSRI treatment for MDD in relation to treatment effect. METHODS: Eight unmedicated patients with moderate to severe MDD underwent PET with the 5-HT1B receptor radioligand [11C]AZ10419369 before and after 3 to 4 weeks of treatment with the SSRI escitalopram 10 mg daily. Depression severity was assessed at time of PET and after 6 to 7 weeks of treatment with the Montgomery-Åsberg Depression Rating Scale. RESULTS: We observed a significant reduction in [11C]AZ10419369 binding in a dorsal brainstem (DBS) region containing the median and dorsal raphe nuclei after escitalopram treatment (P = .036). Change in DBS [11C]AZ10419369 binding correlated with Montgomery-Åsberg Depression Rating Scale reduction after 3-4 (r = 0.78, P = .021) and 6-7 (r = 0.94, P < .001) weeks' treatment. CONCLUSIONS: Our findings align with the previously reported reduction of 5-HT1B receptor binding in the raphe nuclei after SSRI administration and support future studies testing change in DBS 5-HT1B receptor binding as an SSRI treatment response marker.
Asunto(s)
Trastorno Depresivo Mayor , Escitalopram , Tomografía de Emisión de Positrones , Receptor de Serotonina 5-HT1B , Inhibidores Selectivos de la Recaptación de Serotonina , Receptor de Serotonina 5-HT1B/metabolismo , Masculino , Humanos , Trastorno Depresivo Mayor/tratamiento farmacológico , Trastorno Depresivo Mayor/metabolismo , Trastorno Depresivo Mayor/diagnóstico por imagen , Adulto , Femenino , Persona de Mediana Edad , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Escitalopram/farmacología , Escitalopram/metabolismo , Encéfalo/metabolismo , Encéfalo/diagnóstico por imagen , Encéfalo/efectos de los fármacos , Resultado del Tratamiento , Piperazinas/farmacología , Unión Proteica/efectos de los fármacos , Adulto Joven , Citalopram/farmacología , Benzopiranos , MorfolinasRESUMEN
Several lines of evidence are indicative of a role for immune activation in the pathophysiology of schizophrenia. Nevertheless, studies using positron emission tomography (PET) and radioligands for the translocator protein (TSPO), a marker for glial activation, have yielded inconsistent results. Whereas early studies using a radioligand with low signal-to-noise in small samples showed increases in patients, more recent studies with improved methodology have shown no differences or trend-level decreases. Importantly, all patients investigated thus far have been on antipsychotic medication, and as these compounds may dampen immune cell activity, this factor limits the conclusions that can be drawn. Here, we examined 16 drug-naive, first-episode psychosis patients and 16 healthy controls using PET and the TSPO radioligand [11C]PBR28. Gray matter (GM) volume of distribution (VT) derived from a two-tissue compartmental analysis with arterial input function was the main outcome measure. Statistical analyses were performed controlling for both TSPO genotype, which is known to affect [11C]PBR28 binding, and gender. There was a significant reduction of [11C]PBR28 VT in patients compared with healthy controls in GM as well as in secondary regions of interest. No correlation was observed between GM VT and clinical or cognitive measures after correction for multiple comparisons. The observed decrease in TSPO binding suggests reduced numbers or altered function of immune cells in brain in early-stage schizophrenia.
Asunto(s)
Neuroglía/química , Trastornos Psicóticos/diagnóstico por imagen , Receptores de GABA/análisis , Esquizofrenia/metabolismo , Acetamidas , Adulto , Biomarcadores/metabolismo , Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Radioisótopos de Carbono , Estudios de Casos y Controles , Femenino , Sustancia Gris/diagnóstico por imagen , Sustancia Gris/microbiología , Humanos , Masculino , Microglía/metabolismo , Neuroglía/metabolismo , Neuroglía/patología , Tomografía de Emisión de Positrones/métodos , Piridinas , Ensayo de Unión Radioligante , Radiofármacos , Receptores de GABA/metabolismo , Esquizofrenia/diagnóstico por imagen , Esquizofrenia/patologíaRESUMEN
OBJECTIVE: Accumulating evidence implicates immune activation in the development of schizophrenia. Here, monocyte numbers, monocyte chemoattractant protein-1 (MCP-1) and chitinase-3-like protein 1 (YKL-40) were investigated in plasma and cerebrospinal fluid (CSF) in first-episode psychosis (FEP) patients. METHOD: CSF and blood were sampled from 42 first-episode psychosis (FEP) patients and 22 healthy controls. The levels of YKL-40 and MCP-1 were measured using electrochemiluminescence assay, and blood monocytes were counted using an XN-9000-hematology analyzer. RESULTS: We found higher plasma levels of MCP-1 and YKL-40 in FEP patients compared with healthy controls, a condition that was unrelated to antipsychotic and/or anxiolytic medication. This was combined with an increased number of blood monocytes and a borderline significant increase in YKL-40 levels in the CSF of tobacco-free FEP patients. Plasma or CSF chemokines or blood monocytes did not correlate with the severity of symptoms or the level of functioning. CONCLUSION: These data demonstrate activation of monocytes in FEP and strengthens the idea of an immune dysfunction of psychotic disorders. Further studies are required to perceive a role of YKL-40 and MCP-1 in the initiation and progression of schizophrenia.
Asunto(s)
Quimiocina CCL2/sangre , Proteína 1 Similar a Quitinasa-3/sangre , Monocitos , Trastornos Psicóticos/sangre , Esquizofrenia/sangre , Adulto , Quimiocina CCL2/líquido cefalorraquídeo , Proteína 1 Similar a Quitinasa-3/líquido cefalorraquídeo , Femenino , Humanos , Recuento de Leucocitos , Masculino , Trastornos Psicóticos/líquido cefalorraquídeo , Trastornos Psicóticos/inmunología , Esquizofrenia/líquido cefalorraquídeo , Esquizofrenia/inmunología , Adulto JovenRESUMEN
The dopamine (DA) and serotonin (5-HT) neurotransmission systems are of fundamental importance for normal brain function and serve as targets for treatment of major neuropsychiatric disorders. Despite central interest for these neurotransmission systems in psychiatry research, little is known about the regulation of receptor and transporter density levels. This lack of knowledge obscures interpretation of differences in protein availability reported in psychiatric patients. In this study, we used positron emission tomography (PET) in a twin design to estimate the relative contribution of genetic and environmental factors, respectively, on dopaminergic and serotonergic markers in the living human brain. Eleven monozygotic and 10 dizygotic healthy male twin pairs were examined with PET and [(11)C]raclopride binding to the D2- and D3-dopamine receptor and [(11)C]WAY100635 binding to the serotonin 5-HT1A receptor. Heritability, shared environmental effects and individual-specific non-shared effects were estimated for regional D2/3 and 5-HT1A receptor availability in projection areas. We found a major contribution of genetic factors (0.67) on individual variability in striatal D2/3 receptor binding and a major contribution of environmental factors (pairwise shared and unique individual; 0.70-0.75) on neocortical 5-HT1A receptor binding. Our findings indicate that individual variation in neuroreceptor availability in the adult brain is the end point of a nature-nurture interplay, and call for increased efforts to identify not only the genetic but also the environmental factors that influence neurotransmission in health and disease.
Asunto(s)
Receptores Dopaminérgicos/metabolismo , Receptores de Serotonina/metabolismo , Adulto , Disponibilidad Biológica , Encéfalo/metabolismo , Cuerpo Estriado/metabolismo , Dopamina/metabolismo , Interacción Gen-Ambiente , Humanos , Masculino , Piperazinas , Tomografía de Emisión de Positrones/métodos , Piridinas , Racloprida , Receptor de Serotonina 5-HT1A/metabolismo , Receptores de Dopamina D2/metabolismo , Receptores de Dopamina D3/metabolismo , Serotonina/metabolismo , Transmisión Sináptica/fisiología , Gemelos Dicigóticos , Gemelos MonocigóticosRESUMEN
The human brainstem is a complex structure with several small nuclei and neural pathways of interest in the pathophysiology of central nervous system (CNS) disorders. In common with other monoaminergic systems, serotoninergic neurons originate from a group of nuclei located in the brainstem. The present study was designed to validate a user-independent approach for a detailed in vivo quantification of serotonin transporter (5-HTT) availability in the human brainstem using a template-based approach that consisted of three steps. First, 3T-MR images and parametric binding potential (BPND) [(11)C]MADAM images of ten healthy subjects were used to generate a PET template of 5-HTT availability. In the second step, volumes of interest (VOIs) for different brainstem nuclei were obtained using a method in which VOIs are initially delineated on MRI images using anatomical landmarks and then are finally tailored on the distribution of 5-HTT binding using a thresholding approach applied to the 5-HTT template. In the final step, the VOIs were transformed and applied individually to BPND images of 16 healthy subjects (14M/2F, 20-64years). The in vivo distribution of BPND values obtained with the template-based method were in good agreement with an individual-based approach taken as gold standard. Results were also in agreement with 5-HTT quantification using in vitro binding data obtained with autoradiography (ARG) studies using [(3)H]MADAM. The proposed template-based method can be applied to PET data acquired in several CNS disorders in which serotonin neurons in the brainstem might be affected.
Asunto(s)
Autorradiografía/métodos , Bencilaminas/farmacocinética , Tronco Encefálico/metabolismo , Imagen Molecular/métodos , Tomografía de Emisión de Positrones/métodos , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Adulto , Anciano , Autopsia/métodos , Tronco Encefálico/química , Femenino , Humanos , Imagenología Tridimensional/métodos , Imagen por Resonancia Magnética/métodos , Masculino , Persona de Mediana Edad , Radiofármacos/farmacocinética , Proteínas de Transporte de Serotonina en la Membrana Plasmática/química , Distribución TisularRESUMEN
PURPOSE: The PET radioligand [(11)C]PBR28 binds to the translocator protein (TSPO), a marker of brain immune activation. We examined the reproducibility of [(11)C]PBR28 binding in healthy subjects with quantification on a regional and voxel-by-voxel basis. In addition, we performed a preliminary analysis of diurnal changes in TSPO availability. METHODS: Twelve subjects were examined using a high-resolution research tomograph and [(11)C]PBR28, six in the morning and afternoon of the same day, and six in the morning on two separate days. Regional volumes of distribution (V T) were derived using a region-of-interest based two-tissue compartmental analysis (2TCM), as well as a parametric approach. Metabolite-corrected arterial plasma was used as input function. RESULTS: For the whole sample, the mean absolute variability in V T in the grey matter (GM) was 18.3 ± 12.7 %. Intraclass correlation coefficients in GM regions ranged from 0.90 to 0.94. Reducing the time of analysis from 91 to 63 min yielded a variability of 16.9 ± 14.9 %. There was a strong correlation between the parametric and 2TCM-derived GM values (r = 0.99). A significant increase in GM V T was observed between the morning and afternoon examinations when using secondary methods of quantification (p = 0.028). In the subjects examined at the same time of the day, the absolute variability was 15.9 ± 12.2 % for the 91-min 2TCM data. CONCLUSION: V T of [(11)C]PBR28 binding showed medium reproducibility and high reliability in GM regions. Our findings support the use of parametric approaches for determining [(11)C]PBR28 V T values, and indicate that the acquisition time could be shortened. Diurnal changes in TSPO binding in the brain may be a potential confounder in clinical studies and should be investigated further.
Asunto(s)
Radioisótopos de Carbono , Pirimidinas/metabolismo , Receptores de GABA/metabolismo , Femenino , Genotipo , Voluntarios Sanos , Humanos , Masculino , Unión Proteica , Receptores de GABA/genética , Reproducibilidad de los Resultados , Adulto JovenRESUMEN
Dopamine D2 receptor positron emission tomography (PET) radioligands have proven useful for indirect assessment of the endogenous dopamine concentration in the living brain. On the contrary, dopamine D1 receptor antagonist radioligands have shown no sensitivity to changes in the dopamine concentration. A recent approach to enhance the sensitivity of radioligands to the dopamine concentration has been the development of dopamine D2 receptor agonist radioligands. The aim of this study was to evaluate the dopamine sensitivity of a dopamine D1 receptor agonist radioligand. For this purpose, we developed (S)-[¹¹C]N-methyl-NNC 01-0259 ((S)-[¹¹C]1) and characterized the receptor binding of (S)-[¹¹C]1 using in vitro receptor binding assays and in vivo PET measurements in monkeys. In vitro, both enantiomers of 1 were partial dopamine D1 receptor agonists, with (S)-1 having a 10-50 times higher affinity than (R)-1. PET studies in monkey confirmed the stereoselectivity of [¹¹C]1 in vivo. In monkey, administration of the dopamine D1-like receptor antagonist (R)-(+)-SCH 23390 decreased the striatal binding potential of (S)-[¹¹C]1 by 97%, but administration of the dopamine concentration enhancer d-amphetamine did not affect (S)-[¹¹C]1 binding. We conclude that the agonist (S)-[¹¹C]1 provides specific binding to dopamine D1-like receptors, possibly representing binding to the high-affinity state of the receptors. The partial dopamine D1 receptor agonist radioligand has, however, no enhanced sensitivity to endogenous dopamine concentrations in comparison with antagonist radioligands.
Asunto(s)
Benzazepinas/farmacología , Benzofuranos/farmacología , Encéfalo/diagnóstico por imagen , Agonistas de Dopamina/farmacología , Dopamina/metabolismo , Tomografía de Emisión de Positrones , Radiofármacos/farmacología , Receptores de Dopamina D1/agonistas , Animales , Células CHO , Cricetinae , Cricetulus , Humanos , Macaca fascicularis , Unión Proteica , Receptores de Dopamina D1/metabolismoRESUMEN
The need for positron emission tomography (PET)-radioligands that are sensitive to changes in endogenous serotonin (5-HT) levels in brain is recognized in experimental and clinical psychiatric research. We recently developed the novel PET radioligand [(11)C]AZ10419369 that is highly selective for the 5-HT(1B) receptor. In this PET-study in three cynomolgus monkeys, we examined the sensitivity of [(11)C]AZ10419369 to altered endogenous 5-HT levels. Fenfluramine-induced 5-HT release decreased radioligand binding in a dose-dependent fashion with a regional average of 27% after 1 mg/kg and 50% after 5 mg/kg. This preliminary study supports that [(11)C]AZ10419369 is sensitive to endogenous 5-HT levels in vivo and may serve as a tool to examine the pathophysiology and treatment of major psychiatric disorders.
Asunto(s)
Benzopiranos , Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Fenfluramina/farmacología , Morfolinas , Piperazinas , Radiofármacos , Receptor de Serotonina 5-HT1B/metabolismo , Serotoninérgicos/farmacología , Animales , Radioisótopos de Carbono , Relación Dosis-Respuesta a Droga , Femenino , Fenfluramina/administración & dosificación , Macaca fascicularis , Tomografía de Emisión de Positrones , Radiofármacos/farmacocinética , Serotonina/metabolismo , Serotoninérgicos/administración & dosificación , Factores de TiempoRESUMEN
D2 dopamine receptors in the putamen of living human subjects were characterized by using the selective, high-affinity D2 dopamine receptor antagonist carbon-11-labeled raclopride and positron emission tomography. Experiments in four healthy men demonstrated saturability of [11C]raclopride binding to an apparently homogeneous population of sites with Hill coefficients close to unity. In the normal putamen, maximum binding ranged from 12 to 17 picomoles per cubic centimeter and dissociation constants from 3.4 to 4.7 nanomolar. Maximum binding for human putamen at autopsy was 15 picomoles per cubic centimeter. Studies of [11C]raclopride binding indicate that clinically effective doses of chemically distinct neuroleptic drugs result in 85 to 90 percent occupancy of D2 dopamine receptors in the putamen of schizophrenic patients.
Asunto(s)
Encéfalo/metabolismo , Receptores Dopaminérgicos/metabolismo , Tomografía Computarizada de Emisión , Adulto , Animales , Antipsicóticos/metabolismo , Benzamidas/metabolismo , Cerebelo/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Putamen/metabolismo , Racloprida , Receptores de Dopamina D2 , Roedores , Esquizofrenia/metabolismoRESUMEN
Reumatoid Arthritis (RA) is an autoimmune disorder characterized by peripheral joint inflammation. Recently, an engagement of the brain immune system has been proposed. The aim with the current investigation was to study the glial cell activation marker translocator protein (TSPO) in a well characterized cohort of RA patients and to relate it to disease activity, peripheral markers of inflammation and autonomic activity. Fifteen RA patients and fifteen healthy controls matched for age, sex and TSPO genotype (rs6971) were included in the study. TSPO was measured using Positron emission tomography (PET) and the radioligand [11C]PBR28. The outcome measure was total distribution volume (VT) estimated using Logan graphical analysis, with grey matter (GM) as the primary region of interest. Additional regions of interest analyses as well as voxel-wise analyses were also performed. Clinical evaluation of disease activity, symptom assessments, serum analyses of cytokines and heart rate variability (HRV) analysis of 24â¯h ambulatory ECG were performed in all subjects. There were no statistically significant group differences in TSPO binding, either when using the primary outcome VT or when normalizing VT to the lateral occipital cortex (pâ¯>â¯0.05). RA patients had numerically lower VT values than healthy controls (Cohen's D for GMâ¯=â¯-0.21). In the RA group, there was a strong negative correlation between [11C]PBR28 VT in GM and disease activity (DAS28)(râ¯=â¯-0.745, pâ¯=â¯0.002, corrected for rs6971 genotype). Higher serum levels of IFNγ and TNF-α were found in RA patients compared to controls (pâ¯<â¯0.05) and several measures of autonomic activity showed significant differences between RA and controls (pâ¯<â¯0.05). However, no associations between markers of systemic inflammation or autonomic activity and cerebral TSPO binding were found. In conclusion, no statistically significant group differences in TSPO binding as measured with [11C]PBR28 PET were detected. Within the RA group, lower cerebral TSPO binding was associated with higher disease activity, suggesting that cerebral TSPO expression may be related to disease modifying mechanisms in RA. In light of the earlier confirmed neuro-immune features of RA, these results warrant further investigations regarding neuro-immune joint-to-CNS signalling to open up for potentially new treatment strategies.
Asunto(s)
Acetamidas/metabolismo , Artritis Reumatoide/diagnóstico por imagen , Artritis Reumatoide/metabolismo , Radioisótopos de Carbono/metabolismo , Tomografía de Emisión de Positrones/métodos , Piridinas/metabolismo , Receptores de GABA/metabolismo , Adulto , Biomarcadores/metabolismo , Corteza Cerebral/diagnóstico por imagen , Corteza Cerebral/metabolismo , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Unión Proteica/fisiologíaRESUMEN
A large problem in drug discovery is to find relevant in vitro or in vivo animal models and to be able to extrapolate the results obtained to humans. Drug research now benefits from the fast development of imaging technologies that trace radiolabelled molecules directly in the human brain. Positron emission tomography (PET) and allied techniques use molecules that are labelled with short-lived radioisotopes and injected intravenously. The most straightforward approach is to radiolabel a new potential drug and then to trace its anatomical distribution and binding in the brain. An indirect approach is to study how the unlabelled drug inhibits specific radioligand binding. The demonstration of quantitative relationships between drug binding in vivo and drug effects in patients is used to validate targets for drug action and to optimize clinical treatment.
Asunto(s)
Antipsicóticos/farmacología , Unión Competitiva , Salicilamidas/farmacología , Tomografía Computarizada de Emisión , Relación Dosis-Respuesta a Droga , Humanos , Racloprida , InvestigaciónRESUMEN
BACKGROUND: Antipsychotic drugs in depot formulations may prevent psychotic relapses, even after complete withdrawal. To examine the duration of drug remaining in the brain, central D2 dopamine receptor occupancy was measured with positron emission tomography for a year after discontinuation of depot neuroleptic treatment. METHODS: Four schizophrenic patients were withdrawn from low-dose treatment with haloperidol decanoate (30-50 mg every 4 weeks). They were examined repeatedly with positron emission tomography and the radioligand carbon 11-labeled raclopride during the following year. At end point, a Scatchard analysis was performed to determine the density and affinity of D2 dopamine receptors. RESULTS: Occupancy of D2 dopamine receptors was highest 1 week after depot injection (66%, 77%, 82%, and 78% in 4 patients) and then decreased slowly. Six months after discontinuation of treatment, D2 dopamine receptor occupancy was 24%, 32%, and 34% in 3 patients. After 1 year, D2 dopamine receptor density and affinity in 2 patients were within the ranges of control subjects, suggesting no remaining haloperidol. CONCLUSIONS: Our preliminary finding of persistence of D2 dopamine receptor occupancy indicates that commonly used doses of haloperidol decanoate (200 mg every 4 weeks) maintain antipsychotic levels of receptor occupancy even 16 weeks after discontinuation of treatment. This may explain the lower relapse rates in patients withdrawn from depot neuroleptic treatment compared with those withdrawn from oral treatment. In addition, the remaining occupancy may confound the clinical evaluation of subsequent treatments. For controlled clinical trials of new antipsychotic drugs, we suggest a minimum washout of 6 months after the last depot injection.
Asunto(s)
Antipsicóticos/farmacocinética , Encéfalo/diagnóstico por imagen , Haloperidol/análogos & derivados , Receptores de Dopamina D2/metabolismo , Esquizofrenia/tratamiento farmacológico , Adulto , Antipsicóticos/uso terapéutico , Ganglios Basales/diagnóstico por imagen , Ganglios Basales/metabolismo , Encéfalo/metabolismo , Preparaciones de Acción Retardada/farmacocinética , Preparaciones de Acción Retardada/uso terapéutico , Antagonistas de Dopamina , Femenino , Haloperidol/farmacocinética , Haloperidol/uso terapéutico , Humanos , Masculino , Matemática , Persona de Mediana Edad , Putamen/diagnóstico por imagen , Putamen/metabolismo , Racloprida , Ensayo de Unión Radioligante , Receptores de Dopamina D2/análisis , Salicilamidas , Esquizofrenia/diagnóstico por imagen , Esquizofrenia/metabolismo , Tomografía Computarizada de EmisiónRESUMEN
Using positron emission tomography and the carbon 11-labeled ligand raclopride, central D2-dopamine receptor occupancy in the putamen was determined in psychiatric patients treated with clinical doses of psychoactive drugs. Receptor occupancy in drug-treated patients was defined as the percent reduction of specific carbon 11-raclopride binding in relation to the expected binding in the absence of drug treatment. Clinical treatment of schizophrenic patients with 11 chemically distinct antipsychotic drugs (including both classic and atypical neuroleptics such as clozapine) resulted in a 65% to 85% occupancy of D2-dopamine receptors. In a depressed patient treated with the tricyclic antidepressant nortriptyline, no occupancy was found. The time course for receptor occupancy and drug levels was followed after withdrawal of sulpiride or haloperidol. D2-dopamine receptor occupancy remained above 65% for many hours despite a substantial reduction of serum drug concentrations. In a sulpiride-treated patient, the dosage was reduced in four steps over a nine-week period and a curvilinear relationship was demonstrated between central D2-dopamine receptor occupancy and serum drug concentrations. The results demonstrate that clinical doses of all the currently used classes of antipsychotic drugs cause a substantial blockade of central D2-dopamine receptors in humans. This effect appears to be selective for the antipsychotics, since it was not induced by the antidepressant nortriptyline.
Asunto(s)
Antipsicóticos/uso terapéutico , Encéfalo/metabolismo , Receptores Dopaminérgicos/efectos de los fármacos , Esquizofrenia/tratamiento farmacológico , Adulto , Antipsicóticos/metabolismo , Antipsicóticos/farmacología , Encéfalo/diagnóstico por imagen , Radioisótopos de Carbono , Antagonistas de Dopamina , Femenino , Haloperidol/farmacología , Haloperidol/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Nortriptilina/metabolismo , Nortriptilina/farmacología , Putamen/diagnóstico por imagen , Putamen/metabolismo , Radiografía , Receptores Dopaminérgicos/metabolismo , Esquizofrenia/metabolismo , Sulpirida/farmacología , Sulpirida/uso terapéutico , Tomografía Computarizada de EmisiónRESUMEN
Positron emission tomography and selective radioligands were used to determine D1 and D2 dopamine receptor occupancy induced by neuroleptics in the basal ganglia of drug-treated schizophrenic patients. In 22 patients treated with conventional dosages of classical neuroleptics, the D2 occupancy was 70% to 89%. Patients with acute extrapyramidal syndromes had a higher D2 occupancy than those without side effects. This finding indicates that neuroleptic-induced extrapyramidal syndromes are related to the degree of central D2 occupancy induced in the basal ganglia. In five patients treated with clozapine, the prototype atypical antipsychotic drug, a lower D2 occupancy of 38% to 63% was found. This finding demonstrates that clozapine is also "atypical" with respect to the central D2 occupancy in patients. During treatment with clozapine, there is a low frequency of extrapyramidal syndromes, which accordingly may reflect the comparatively low D2 occupancy induced by clinical doses of clozapine. Classical neuroleptics, like haloperidol or sulpiride, did not cause any evident D1 occupancy, but the thioxanthene flupentixol induced a 36% to 44% occupancy. In four patients treated with clozapine, the D1 occupancy was 38% to 52%. The D1 occupancy induced by clozapine and flupentixol may contribute to the antipsychotic effect of these drugs.
Asunto(s)
Antipsicóticos/metabolismo , Enfermedades de los Ganglios Basales/inducido químicamente , Clozapina/metabolismo , Receptores Dopaminérgicos/metabolismo , Tomografía Computarizada de Emisión , Adolescente , Adulto , Antipsicóticos/efectos adversos , Antipsicóticos/uso terapéutico , Ganglios Basales/efectos de los fármacos , Ganglios Basales/metabolismo , Enfermedades de los Ganglios Basales/metabolismo , Enfermedades de los Ganglios Basales/fisiopatología , Benzazepinas/metabolismo , Clozapina/efectos adversos , Clozapina/uso terapéutico , Antagonistas de Dopamina , Femenino , Humanos , Radioisótopos de Yodo/metabolismo , Masculino , Putamen/efectos de los fármacos , Putamen/metabolismo , Racloprida , Receptores Dopaminérgicos/efectos de los fármacos , Salicilamidas/metabolismo , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/metabolismoRESUMEN
Several groups have reported increased densities of D2 dopamine receptors in the basal ganglia of schizophrenic brains postmortem. The significance of this finding has been questioned, since an upregulation of receptor number may be a neuronal response to neuroleptic drug treatment. We have used positron emission tomography and [11C]raclopride to examine central D2 dopamine receptor binding in 20 healthy subjects and 18 newly admitted, young, neuroleptic-naive patients with schizophrenia. An in vivo saturation procedure was applied for quantitative determination of D2 dopamine receptor density (Bmax) and affinity (Kd). When the two groups were compared, no significant difference in Bmax or Kd values was found in the putamen or the caudate nucleus. The hypothesis of generally elevated central D2 dopamine receptor densities in schizophrenia was thus not supported by the present findings. In the patients but not in the healthy controls, significantly higher densities were found in the left than in the right putamen but not in the caudate nucleus.
Asunto(s)
Antipsicóticos/uso terapéutico , Ganglios Basales/metabolismo , Receptores Dopaminérgicos/metabolismo , Esquizofrenia/metabolismo , Adulto , Ganglios Basales/diagnóstico por imagen , Radioisótopos de Carbono , Núcleo Caudado/diagnóstico por imagen , Núcleo Caudado/metabolismo , Dopamina/fisiología , Femenino , Humanos , Masculino , Putamen/diagnóstico por imagen , Putamen/metabolismo , Racloprida , Receptores de Dopamina D2 , Salicilamidas/metabolismo , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/fisiopatología , Tomografía Computarizada de Emisión , Regulación hacia ArribaRESUMEN
The relationship between central D2-dopamine receptor occupancy and antipsychotic drug effects was examined in a double-blind study. Raclopride was the compound used to induce a selective occupancy of the D2-dopamine receptors. In addition, 11C-labeled raclopride was the radioligand used to measure occupancy by positron emission tomography (PET). Seventeen schizophrenic patients were randomly assigned to one of three parallel groups treated for 4 weeks with daily doses of 2, 6, or 12 mg of raclopride. D2-receptor occupancy was determined by PET at steady-state conditions in 13 patients who completed the study. A statistically significant relationship was demonstrated between antipsychotic effect and degree of D2-receptor occupancy (p < 0.05). Patients with extrapyramidal side effects had significantly higher D2-receptor occupancy than those without (p = 0.02). The finding of a relationship between selective occupancy of the D2-dopamine receptors and clinical effects in schizophrenic patients principally provides new support for the dopamine hypothesis of antipsychotic drug action.
Asunto(s)
Antipsicóticos/uso terapéutico , Encéfalo/diagnóstico por imagen , Receptores de Dopamina D2/efectos de los fármacos , Salicilamidas/uso terapéutico , Esquizofrenia/diagnóstico por imagen , Adulto , Antipsicóticos/efectos adversos , Antipsicóticos/sangre , Antagonistas de los Receptores de Dopamina D2 , Método Doble Ciego , Femenino , Humanos , Masculino , Escalas de Valoración Psiquiátrica , Racloprida , Salicilamidas/efectos adversos , Salicilamidas/sangre , Esquizofrenia/tratamiento farmacológico , Psicología del Esquizofrénico , Tomografía Computarizada de EmisiónRESUMEN
[11C]Raclopride binding to central D2-dopamine receptors in humans has previously been examined by positron emission tomography (PET). Based on the rapid occurrence of binding equilibrium, a saturation analysis has been developed for the determination of receptor density (Bmax) and affinity (Kd). For analysis of PET measurements obtained with other ligands, a kinetic three-compartment model has been used. In the present study, the brain uptake of [11C]raclopride was analyzed further by applying both a kinetic and an equilibrium analysis to data obtained from four PET experiments in each of three healthy subjects. First regional CBV was determined. In the second and third experiment, [11C]-raclopride with high and low specific activity was used. In a fourth experiment, the [11C]raclopride enantiomer [11C]FLB472 was used to examine the concentration of free radioligand and nonspecific binding in brain. Radio-activity in arterial blood was measured using an automated blood sampling system. Bmax and Kd values for [11C]raclopride binding could be determined also with the kinetic analysis. As expected theoretically, those values were similar to those obtained with the equilibrium analysis. In addition, the kinetic analysis allowed separate determination of the association and dissociation rate constants, kon and koff, respectively. Examination of [11C]raclopride and [11C]FLB472 uptake in brain regions devoid of specific D2-dopamine receptor binding indicated a fourth compartment in which uptake was reversible, nonstereoselective, and nonsaturable in the dose range studied.
Asunto(s)
Encéfalo/metabolismo , Receptores Dopaminérgicos/metabolismo , Salicilamidas/metabolismo , Tomografía Computarizada de Emisión , Adulto , Encéfalo/diagnóstico por imagen , Radioisótopos de Carbono , Humanos , Isomerismo , Cinética , Modelos Biológicos , Racloprida , Receptores de Dopamina D2RESUMEN
Several approaches have been applied for quantification of D2 dopamine receptors in positron emission tomography studies using [11C]raclopride. Initial approaches were based on analyses of data obtained after rapid bolus injection of [11C]raclopride. A continuous infusion paradigm has more recently been applied. The current study compares these approaches in healthy men. Two positron emission tomography measurements were performed in each of six healthy men, the first with rapid bolus injection and the second with continuous infusion of [11C]raclopride. In rapid bolus injection, the binding potential was calculated by the following methods. One approach is the kinetic analysis using the standard three-compartment model. Another is to define a transient equilibrium at the moment when the specific binding reaches its maximum. In continuous infusion, binding potential was calculated by using time-activity data at equilibrium condition. All methods gave almost identical binding potential, representing cross-validation of these methods. The continuous infusion method can provide "true" equilibrium condition. The kinetic analysis is a sophisticated approach but requires determination of an arterial input function. The transient equilibrium method thus is suitable for routine clinical research, since it does not require determination of an arterial input function.
Asunto(s)
Antagonistas de Dopamina/metabolismo , Receptores de Dopamina D2/metabolismo , Salicilamidas/metabolismo , Tomografía Computarizada de Emisión/métodos , Adulto , Radioisótopos de Carbono , Fenómenos Químicos , Química , Humanos , Infusiones Intravenosas , Inyecciones Intravenosas , Masculino , Racloprida , Ensayo de Unión Radioligante , Valores de ReferenciaRESUMEN
Positron emission tomography (PET) has hitherto been used to examine D2 dopamine receptor binding in the striatum, a region with a high density of receptors. Research has been hampered by the lack of suitable radioligands for detection of the low-density D2 dopamine receptor populations in the limbic and cortical dopamine systems that are implicated in the pathophysiology of schizophrenia. [11C]FLB 457 is a new radioligand with the very high affinity of 20 pmol/L (K(i)) for the D2 and D3 dopamine receptor subtypes. This study in eight healthy subjects was designed to evaluate the suitability of [11C]FLB 457 for quantification of extrastriatal D2/D3 dopamine receptors. PET-data were acquired in the three-dimensional mode and the arterial input function was corrected for labeled metabolites. The standard three-compartment model and four derived approaches were applied to calculate and compare the binding potentials. Besides the striatum, conspicuous radioactivity was found in extrastriatal regions such as the thalamus, the anterior cinguli, and the temporal and frontal cortices. The time activity curves could be described by the three compartment model. The different approaches gave similar binding potential values and the rank order between regions was consistent with that found in vitro. The short time of a PET measurement using [11C]FLB 457 (63 minutes) seemed not to be sufficient for reliable determination of the high binding potential in the striatum. These results are of principal importance because they show the potential for PET quantification of minute receptor populations in the human brain.
Asunto(s)
Antagonistas de Dopamina , Putamen/química , Pirrolidinas , Receptores de Dopamina D2/metabolismo , Salicilamidas , Tomografía Computarizada de Emisión/métodos , Adulto , Sitios de Unión , Radioisótopos de Carbono , Cerebelo/química , Cerebelo/metabolismo , Humanos , Cinética , Masculino , Putamen/metabolismo , Estándares de Referencia , Lóbulo Temporal/química , Lóbulo Temporal/metabolismo , Tálamo/química , Tálamo/metabolismo , Tomografía Computarizada de Emisión/normasRESUMEN
Loss of dopamine D2-like receptors in the striatum has been associated with both normal human aging and impairment of cognitive and motor functions in the elderly. To investigate whether there are age-associated changes in dopamine D2 and D3 receptor subtypes (D2/3Rs) outside the striatum, a D2/3R selective high-affinity radioligand [11C]FLB 457 was used in positron emission tomography (PET) examinations for 24 normal healthy male subjects (age range 19-74 years). Significant age-related declines of D2/3Rs were detected in all the brain regions studied: the anterior cingulate cortex (decline of 13% per increase of a decade in age, P < 0.001). the frontal cortex (11%, P < 0.001), the lateral temporal cortex (10%, P < 0.001), the hippocampus (10%, P < 0.01), the medial temporal cortex (9%, P < 0.001), the amygdala (7%, P < 0.01), the medial thalamus (6%, P < 0.001) and the lateral thalamus (5%, P < 0.01). The rate of D2/3R decline was significantly faster in the frontal cortex as compared to the medial temporal cortex (P < 0.05, Bonferroni corrected) and as compared to the medial thalamus (P < 0.05, Bonferroni corrected). These results indicate that the previously demonstrated age-related decline in striatal dopamine D2 receptors extends to several extrastriatal regions in normal human males. Further, the rate of D2/3R decline may be faster in the frontal cortex as compared to the temporal and thalamic regions.